Material Agreements (Details) - USD ($) $ in Thousands							1 Months Ended	2 Months Ended	3 Months Ended			9 Months Ended		17 Months Ended	29 Months Ended	47 Months Ended
	Mar. 27, 2023	Mar. 02, 2023	Oct. 26, 2022	Sep. 26, 2022	Nov. 03, 2020	Apr. 01, 2016	Jun. 30, 2024	Dec. 31, 2020	Sep. 30, 2024	Sep. 30, 2023	Mar. 31, 2023	Sep. 30, 2024	Sep. 30, 2023	Feb. 20, 2019	Mar. 31, 2023	Sep. 30, 2024	May 17, 2022	Mar. 03, 2022
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Interest income and other income, net									$ 979	$ 1,514		$ 2,703	$ 16,156
Manufacture and supply									4,437	4,798		13,352	16,152
Royalties related to the sale of future revenue									13,542	13,002		45,694	37,377
Chief Executive Officer
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Severance costs monthly payment, duration																	18 months
Severance costs											$ 274
Assertio Holdings, Inc
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Royalties related to the sale of future revenue			$ 6,000
Proceeds from collaborators			$ 9,000
Manufacture and supply revenue
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Royalties related to the sale of future revenue									10,671	11,409		29,312	32,807
License and royalty revenue
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Royalties related to the sale of future revenue									2,162	1,103		$ 14,514	3,503
Commercial exploitation agreement with Indivior
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
License agreement term												7 years
Automatic renewal period of agreement		1 year										1 year
Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Indivior
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Deferred income										$ 5,482			5,482
Revenue from collaborative arrangement, excluding revenue from contract with customer													11,482
Interest income and other income, net													6,000
Manufacture and supply													5,482
Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | Manufacture and supply revenue | Indivior
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Revenue from collaborative arrangement, excluding revenue from contract with customer													4,396
Deferred income, revenue recognized													$ 1,682
Supplemental agreement with Indivior
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Aggregate payment														$ 40,750
License agreement with Sunovion Pharmaceuticals, Inc.
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Aggregate payment						$ 22,000
License agreement with Sunovion Pharmaceuticals, Inc. upfront
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Aggregate payment						5,000
License agreement with Sunovion Pharmaceuticals, Inc milestones
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Aggregate payment						17,000
License agreement with Sunovion Pharmaceuticals, Inc milestones | License and royalty revenue
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Royalties related to the sale of future revenue						$ 4,000
MAM Pangolin Royalty , LLC | Monetization Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Proceeds from sale of future revenue					$ 40,000			$ 10,000							$ 50,000	$ 50,000
Proceeds from debt, contingent on additional milestones					75,000
MAM Pangolin Royalty , LLC | Maximum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Proceeds from sale of future revenue					$ 125,000
Haisco Pharmaceutical Group Co., Ltd, upfront payment
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Receivable																		$ 7,000
Sales commissions and fees									134			$ 134
Revenue recognized									$ 7,000			7,000
License & Supply Agreement | Atnahs Pharma UK Limited
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Proceeds from sale of future revenue				$ 3,500
Atnahs Pharma UK Limited, Amended Agreement | License & Supply Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Proceeds from sale of future revenue	$ 2,000
Mitsubishi Tanabe Pharma America, Inc
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Sales commissions and fees												$ 57
Revenue recognized							$ 3,317